Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors
Uloženo v:
| Název: | Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors |
|---|---|
| Autoři: | Moret, E., Ambresin, A., Gianniou, C., Bijon, J., Besse-Hayat, C., Bogiatzi, S., Hohl, D., Spertini, F., Mantel, I. |
| Zdroj: | Graefes Arch Clin Exp Ophthalmol Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, vol. 260, no. 3, pp. 1005-1014 |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2021. |
| Rok vydání: | 2021 |
| Témata: | Vascular Endothelial Growth Factor A, 0301 basic medicine, Recombinant Fusion Proteins, Angiogenesis Inhibitors, Medical Ophthalmology, 3. Good health, Bevacizumab, Drug Hypersensitivity, 03 medical and health sciences, Receptors, Vascular Endothelial Growth Factor, 0302 clinical medicine, Ranibizumab, Intravitreal Injections, Humans, Angiogenesis Inhibitors/adverse effects, Bevacizumab/adverse effects, Drug Hypersensitivity/diagnosis, Drug Hypersensitivity/drug therapy, Drug Hypersensitivity/etiology, Ranibizumab/adverse effects, Retrospective Studies, Aflibercept, Cutaneous adverse events, Drug hypersensitivity reaction, Intravitreal anti-VEGF |
| Popis: | Purpose To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs). Patients and methods Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept. Results Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence. Conclusion Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1435-702X 0721-832X |
| DOI: | 10.1007/s00417-021-05353-3 |
| Přístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s00417-021-05353-3.pdf https://pubmed.ncbi.nlm.nih.gov/34529134 https://www.ncbi.nlm.nih.gov/pubmed/34529134 https://link.springer.com/article/10.1007%2Fs00417-021-05353-3 https://link.springer.com/content/pdf/10.1007/s00417-021-05353-3.pdf https://serval.unil.ch/notice/serval:BIB_C16845CB364E https://serval.unil.ch/resource/serval:BIB_C16845CB364E.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_C16845CB364E7 |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . |
| Přístupové číslo: | edsair.doi.dedup.....529c6b5a977d8835c87d10ef0eb66245 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Purpose To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs). Patients and methods Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept. Results Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence. Conclusion Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease. |
|---|---|
| ISSN: | 1435702X 0721832X |
| DOI: | 10.1007/s00417-021-05353-3 |